Literature DB >> 7860408

Radiation therapy for primary orbital lymphoma.

C K Chao1, H S Lin, V R Devineni, M Smith.   

Abstract

PURPOSE: The influence of tumor size, grade, thoroughness of staging workup, and radiation dose on disease control, radiation-related complications, and incidence of systemic progression of primary orbital lymphoma is analyzed. METHODS AND MATERIALS: Twenty patients with Stage I primary orbital lymphoma were treated from August 1976 through August 1991 at Mallinckrodt Institute of Radiology. Staging workups included physical examination, chest x-ray, complete blood count (CBC), liver function test, and computerized tomography (CT) scan of the orbit, abdomen, and pelvis. Nineteen patients had bone marrow biopsy. The histological types based on the National Cancer Institute working formulation were 9 low-grade and 11 intermediate-grade, including five lymphocytic lymphomas of intermediate differentiation. The extension of disease and the volume of tumor were evaluated by CT scan of the orbit. The most commonly used radiation therapy technique was single anterior direct field with 4 MV or 6 MV photons. Lens was shielded or not treated in eight patients. Dose ranged from 20 to 43.2 Gy. Thirteen of 20 patients received 30 Gy. Minimum follow-up was 24 months (median, 4 years).
RESULTS: Local control was achieved in all 20 patients. One patient with lymphocytic lymphoma with intermediate differentiation developed disseminated disease. Actuarial disease-free survival (DFS) was 100% and 90% at 2 and 5 years, respectively. No retinopathy was observed. Cataracts were noted in seven patients at 1 to 10 years following irradiation (median, 2 years). Three patients developed lacrimal function disorder; however, no corneal ulceration occurred.
CONCLUSIONS: Thirty Gy in 15 fractions appears to be a sufficient dose for local control with acceptable morbidity, especially for low-grade, as well as certain types of intermediate-grade lymphomas, such as diffuse small cleaved cell and lymphocytic lymphoma of intermediate differentiation. Systemic dissemination is minimal, provided local control is achieved and initial staging workups are adequate.

Entities:  

Mesh:

Year:  1995        PMID: 7860408     DOI: 10.1016/0360-3016(94)00416-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Intensity-modulated radiation therapy for orbital lymphoma.

Authors:  Sharad Goyal; Alan Cohler; Jayne Camporeale; Venkat Narra; Ning J Yue
Journal:  Radiat Med       Date:  2009-01-08

2.  The clinical characteristics and treatment results of ocular adnexal lymphoma.

Authors:  Jung-Min Woo; Chien-Kue Tang; Mee-Sook Rho; Jin-Hwa Lee; Hyuk-Chan Kwon; Hee-Bae Ahn
Journal:  Korean J Ophthalmol       Date:  2006-03

3.  Lacrimal gland lymphoma: Role of radiation therapy.

Authors:  Natasha Townsend; Aruna Turaka; Mitchell R Smith
Journal:  Oman J Ophthalmol       Date:  2012-01

4.  Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer.

Authors:  Zhenxiang Deng; Lanxiao Shen; Xiaomin Zheng; Yongqiang Zhou; Jinling Yi; Ce Han; Congying Xie; Xiance Jin
Journal:  Radiat Oncol       Date:  2017-05-10       Impact factor: 3.481

5.  Orbital lymphoma: diagnostic approach and treatment outcome.

Authors:  André M Eckardt; Juliana Lemound; Majeed Rana; Nils-Claudius Gellrich
Journal:  World J Surg Oncol       Date:  2013-03-18       Impact factor: 2.754

Review 6.  Orbital lymphoma: role of radiation.

Authors:  B S Yadav; S C Sharma
Journal:  Indian J Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 1.848

7.  Radiation therapy in primary orbital lymphoma: a single institution retrospective analysis.

Authors:  Luigi De Cicco; Laura Cella; Raffaele Liuzzi; Raffaele Solla; Antonio Farella; Giorgio Punzo; Fausto Tranfa; Diego Strianese; Manuel Conson; Giulio Bonavolontà; Marco Salvatore; Roberto Pacelli
Journal:  Radiat Oncol       Date:  2009-12-07       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.